NCT06720532View on ClinicalTrials.gov

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2031

Conditions
Kidney DiseaseRadiation NephropathyMetastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
DIAGNOSTIC_TEST

characterization of renal function.

Blood and urine sample collection

DIAGNOSTIC_TEST

Handgrip strength test

Assess the peak isometric strength of the hand and forearm muscles, as well as their susceptibility to fatigue.

DIAGNOSTIC_TEST

Questionaires

The questionnaires evaluate quality of life, psychological distress, fear of progression, frailty, pain, decision regret and treatment expectations.

Trial Locations (1)

Unknown

RECRUITING

Klinikum rechts der Isar, München, Bavaria 81675, Munich

All Listed Sponsors
lead

Hannah Schaefer

OTHER

NCT06720532 - Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial | Biotech Hunter | Biotech Hunter